GMED
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 2 purchase disclosures year to date, a thin reading
- Financial indicators Supports a bullish reading. Current ratio 4.26 · operating margin 16%
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
VENTE TOTALE: 55 000 titres (~4 413 467,00 $ US)
- Insiders
- TOBIN JAMES RZARRILLI STEPHEN T
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,413,467
Avg sell (VWAP, 90d window) $80.24 vs last close $74.52 (-7.1%)
- Last activity
- 2026-09-15
- Liquidity
- Liquid $112,776,888/day · 20d vol
- Last synced
-
2026-09-25 21:10:30
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-15 | TOBIN JAMES R | Sell | 30,000 | $74.58 | $2,237,502 | Form 4 |
| 2026-08-18 | ZARRILLI STEPHEN T | Sell | 25,000 | $87.04 | $2,175,965 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-20
GMED presents a compelling combination of strong financial health (liquidity score 90, fundamentals score 85) with meaningful margin expansion and a robust balance sheet, but the earnings catalyst conviction is tempered…
The first sentence of the analysis written for GMED on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 67.4% | 58.9% | 65.1% | 74.2% | 75.0% | |
| Ebit Margin | 20.8% | 8.7% | 12.9% | 23.1% | 20.3% | |
| Ebitda Margin | 24.8% | 18.8% | 22.1% | 29.8% | 27.6% | |
| Operating Profit Margin | 16.3% | 6.6% | 8.5% | 22.3% | 17.9% | |
| Pretax Profit Margin | 20.8% | 4.8% | 10.5% | 23.8% | 18.8% | |
| Continuous Operations Profit Margin | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | |
| Net Profit Margin | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | |
| Bottom Line Profit Margin | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | |
| Current Ratio | 4.264 | 2.544 | 4.882 | 6.177 | 6.168 | |
| Quick Ratio | 2.741 | 1.774 | 2.720 | 4.299 | 4.477 | |
| Solvency Ratio | 0.902 | 0.332 | 0.246 | 1.125 | 1.015 | |
| Cash Ratio | 1.055 | 0.916 | 1.191 | 0.945 | 1.377 | |
| Price To Earnings Ratio | 21.937 | 108.829 | 48.890 | 39.296 | 48.784 | |
| Price To Earnings Growth Ratio | 0.052 | -3.595 | -1.155 | 1.419 | 1.153 | |
| Forward Price To Earnings Growth Ratio | 0.052 | -3.595 | -1.155 | 1.419 | 1.153 | |
| Price To Earnings Diluted Ratio | 22.273 | 110.280 | 49.804 | 40.146 | 50.139 | |
| Price To Earnings Diluted Growth Ratio | 0.053 | -3.687 | -1.181 | 1.410 | 1.178 | |
| Price To Book Ratio | 2.580 | 2.687 | 1.507 | 4.041 | 4.177 | |
| Price To Sales Ratio | 4.015 | 4.456 | 3.842 | 7.295 | 7.591 | |
| Price To Free Cash Flow Ratio | 20.042 | 27.704 | 36.474 | 71.459 | 33.153 | |
| Price To Operating Cash Flow Ratio | 15.661 | 21.562 | 24.749 | 41.810 | 26.325 | |
| Debt To Assets Ratio | 0.022 | 0.102 | 0.102 | 0.003 | 0.000 | |
| Debt To Equity Ratio | 0.026 | 0.129 | 0.130 | 0.003 | 0.000 | |
| Debt To Capital Ratio | 0.025 | 0.114 | 0.115 | 0.003 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.022 | 0.000 | 0.095 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.160 | 1.257 | 1.272 | 1.124 | 1.124 | |
| Working Capital Turnover Ratio | 1.994 | 1.771 | 1.336 | 1.321 | 1.344 | |
| Operating Cash Flow Ratio | 1.511 | 0.608 | 0.621 | 1.121 | 1.971 | |
| Operating Cash Flow Sales Ratio | 0.256 | 0.207 | 0.155 | 0.174 | 0.288 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.781 | 0.778 | 0.679 | 0.585 | 0.794 | |
| Debt Service Coverage Ratio | 0.000 | 1.019 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 39.625 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 1.174 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 6.350 | 0.969 | 0.468 | 29.690 | 0.000 | |
| Capital Expenditure Coverage Ratio | 4.575 | 4.510 | 3.111 | 2.410 | 4.856 | |
| Dividend Paid And Capex Coverage Ratio | 4.575 | 4.510 | 3.111 | 2.410 | 4.856 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 15.608 | 23.175 | 17.541 | 24.031 | 26.744 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 67.4% | ▲8.5% | ▼-0.7% |
| Ebit Margin | 20.8% | ▲12.0% | ▲3.6% |
| Ebitda Margin | 24.8% | ▲6.0% | ▲0.2% |
| Operating Profit Margin | 16.3% | ▲9.7% | ▲2.0% |
| Pretax Profit Margin | 20.8% | ▲16.0% | ▲5.0% |
| Continuous Operations Profit Margin | 18.3% | ▲14.2% | ▲5.4% |
| Net Profit Margin | 18.3% | ▲14.2% | ▲5.4% |
| Bottom Line Profit Margin | 18.3% | ▲14.2% | ▲5.4% |
| Current Ratio | 4.264 | ▲1.720 | ▼-0.543 |
| Quick Ratio | 2.741 | ▲0.967 | ▼-0.461 |
| Solvency Ratio | 0.902 | ▲0.570 | ▲0.178 |
| Cash Ratio | 1.056 | ▲0.139 | ▼-0.042 |
| Price To Earnings Ratio | 21.937 | ▼-86.892 | ▼-31.610 |
| Price To Earnings Growth Ratio | 0.052 | ▲3.646 | ▲0.477 |
| Forward Price To Earnings Growth Ratio | 0.052 | ▲3.646 | ▲0.477 |
| Price To Earnings Diluted Ratio | 22.273 | ▼-88.007 | ▼-32.255 |
| Price To Earnings Diluted Growth Ratio | 0.053 | ▲3.740 | ▲0.498 |
| Price To Book Ratio | 2.580 | ▼-0.107 | ▼-0.418 |
| Price To Sales Ratio | 4.015 | ▼-0.441 | ▼-1.425 |
| Price To Free Cash Flow Ratio | 20.042 | ▼-7.662 | ▼-17.724 |
| Price To Operating Cash Flow Ratio | 15.661 | ▼-5.900 | ▼-10.360 |
| Debt To Assets Ratio | 0.022 | ▼-0.080 | ▼-0.024 |
| Debt To Equity Ratio | 0.026 | ▼-0.103 | ▼-0.032 |
| Debt To Capital Ratio | 0.025 | ▼-0.089 | ▼-0.026 |
| Long Term Debt To Capital Ratio | 0.022 | ▲0.022 | ▼-0.001 |
| Financial Leverage Ratio | 1.159 | ▼-0.098 | ▼-0.028 |
| Working Capital Turnover Ratio | 1.994 | ▲0.222 | ▲0.440 |
| Operating Cash Flow Ratio | 1.511 | ▲0.903 | ▲0.345 |
| Operating Cash Flow Sales Ratio | 0.256 | ▲0.050 | ▲0.040 |
| Free Cash Flow Operating Cash Flow Ratio | 0.781 | ▲0.003 | ▲0.058 |
| Debt Service Coverage Ratio | 0.000 | ▼-1.019 | ▼-0.204 |
| Interest Coverage Ratio | 0.000 | ▼-39.625 | ▼-7.925 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-1.174 | ▼-0.235 |
| Operating Cash Flow Coverage Ratio | 6.350 | ▲5.381 | ▼-1.146 |
| Capital Expenditure Coverage Ratio | 4.575 | ▲0.065 | ▲0.683 |
| Dividend Paid And Capex Coverage Ratio | 4.575 | ▲0.065 | ▲0.683 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 15.608 | ▼-7.567 | ▼-5.812 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $11.80B | $11.23B | $6.03B | $7.46B | $7.27B | |
| Enterprise value | $11.39B | $10.98B | $6.08B | $7.32B | $7.08B | |
| EV / Sales | 3.88x | 4.36x | 3.88x | 7.15x | 7.39x | |
| EV / Op. cash flow | 15.12x | 21.09x | 24.97x | 41.00x | 25.63x | |
| EV / Free cash flow | 19.35x | 27.09x | 36.80x | 70.08x | 32.27x | |
| EV / EBITDA | 15.61x | 23.18x | 17.54x | 24.03x | 26.74x | |
| Net debt / EBITDA | -0.56x | -0.52x | 0.15x | -0.47x | -0.73x | |
| Current ratio | 4.26x | 2.54x | 4.88x | 6.18x | 6.17x | |
| Income quality | 1.40x | 5.06x | 1.98x | 0.94x | 1.85x | |
| Graham number | $55 | $23 | $29 | $28 | $24 | |
| Graham net-net | $6 | $4 | $2 | $5 | $5 | |
| Tax burden | 88.2% | 85.3% | 74.3% | 78.3% | 82.7% | |
| Interest burden | 100.0% | 54.9% | 81.9% | 102.9% | 92.6% | |
| Working capital | $1.63B | $1.32B | $1.52B | $824.1M | $724.4M | |
| Invested capital | $4.44B | $4.16B | $4.53B | $1.33B | $1.19B | |
| Return on assets | 10.1% | 2.0% | 2.4% | 9.2% | 7.6% | |
| Operating ROA | 9.1% | 3.2% | 3.7% | 11.3% | 9.5% | |
| Return on tangible assets | 17.2% | 3.4% | 4.5% | 10.5% | 8.7% | |
| Return on equity | 11.8% | 2.5% | 3.1% | 10.3% | 8.6% | |
| Return on invested capital | 8.8% | 2.9% | 2.1% | 9.3% | 7.8% | |
| Return on capital employed | 10.0% | 3.8% | 2.8% | 11.9% | 9.5% | |
| Earnings yield | 4.6% | 0.9% | 2.0% | 2.5% | 2.1% | |
| Free cash flow yield | 5.0% | 3.6% | 2.7% | 1.4% | 3.0% | |
| Capex / Op. cash flow | 21.9% | 22.2% | 32.1% | 41.5% | 20.6% | |
| Capex / Depreciation | 59.5% | 45.4% | 54.1% | 108.5% | 81.4% | |
| Capex / Sales | 5.6% | 4.6% | 5.0% | 7.2% | 5.9% | |
| SG&A / Sales | 44.8% | 38.9% | 41.0% | 42.2% | 42.6% | |
| R&D / Sales | 6.3% | 6.5% | 7.9% | 7.1% | 10.2% | |
| Stock comp / Sales | 1.7% | 2.2% | 3.4% | 3.2% | 3.2% | |
| Intangibles / Total assets | 41.1% | 42.4% | 46.4% | 12.6% | 12.7% | |
| Days sales outstanding | 92d | 84d | 117d | 78d | 63d | |
| Days payables outstanding | 38d | 26d | 38d | 50d | 33d | |
| Operating cycle | 382d | 316d | 682d | 491d | 425d | |
| Cash conversion cycle | 344d | 290d | 644d | 441d | 391d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+5.1%EV / Sales ▼-11.0%EV / EBITDA ▼-32.7%EV / Op. cash flow ▼-5.966Earnings yield ▲+0.036Graham number ▲+32.125
Profitability
Return on equity ▲+0.093Return on assets ▲+0.082Return on invested capital ▲+0.059Return on capital employed ▲+0.062Operating ROA ▲+0.059Income quality ▼-3.655Tax burden ▲+0.029
Efficiency
Days sales outstanding ▲+8.573Days payables outstanding ▲+11.192Operating cycle ▲+65.544Cash conversion cycle ▲+54.352Capex / Sales ▲+0.010R&D / Sales ▼-0.002
Balance-sheet strength
Current ratio ▲+1.720Net debt / EBITDA ▼-0.036Working capital ▲+305765000.000Invested capital ▲+275040000.000Intangibles / Total assets ▼-0.013
Change over 5 years
Valuation
Market cap ▲+62.2%EV / Sales ▼-47.5%EV / EBITDA ▼-41.6%EV / Op. cash flow ▼-10.506Earnings yield ▲+0.025Graham number ▲+31.046
Profitability
Return on equity ▲+0.032Return on assets ▲+0.025Return on invested capital ▲+0.010Return on capital employed ▲+0.005Operating ROA ▼-0.004Income quality ▼-0.451Tax burden ▲+0.055
Efficiency
Days sales outstanding ▲+29.254Days payables outstanding ▲+4.172Operating cycle ▼-43.010Cash conversion cycle ▼-47.182Capex / Sales ▼-0.003R&D / Sales ▼-0.039
Balance-sheet strength
Current ratio ▼-1.904Net debt / EBITDA ▲+0.171Working capital ▲+902760000.000Invested capital ▲+3241651000.000Intangibles / Total assets ▲+0.284
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-19 | Gilbert Cisneros | Buy | $15,001 - $50,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-19 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2026-03-03 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-07-10 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-24 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-04-09 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-03 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Sale (Full) | $15,001 - $50,000 |
| 2023-02-08 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-11 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2020-06-01 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-05-28 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-03-31 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-02-21 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2019-07-30 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-07-26 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2018-06-19 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2018-06-18 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2018-04-10 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
Recent news
- 2026-09-16 What Makes Globus Medical (GMED) a New Strong Buy Stock Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 2026-09-15 Top Robotics Stocks to Add to Your Portfolio for Impressive Returns Robotics is poised for robust long-term growth. Consider NVDA, TER, ZBRA and GMED for potential market dominance across sectors.
- 2026-09-14 GMED vs. ITGR: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Integer (ITGR). But which of these two companies is the best option for those looking for undervalued stocks?
- 2026-09-14 Why Globus Medical (GMED) is a Top Value Stock for the Long-Term Whether you''re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 2026-09-11 New Strong Buy Stocks for September 11th RCMT, HCSG, BLMN, AGX and GMED have been added to the Zacks Rank #1 (Strong Buy) List on September 11, 2026.
- 2026-09-09 3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
- 2026-09-09 3 Sales Growth Stocks to Buy Amid Renewed Middle East Tensions Globus Medical, NetApp and Assurant stand out for sustainable sales growth, strong cash flow and favorable valuation and profitability screens.
- 2026-09-09 New Strong Buy Stocks for September 9th BP, CRD.B, HCSG, TILE and GMED have been added to the Zacks Rank #1 (Strong Buy) List on September 9, 2026.
- 2026-09-03 Globus Medical Announces CE Mark for Excelsius3D™ Imaging System Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union
- 2026-09-02 3 Reasons Growth Investors Will Love Globus Medical (GMED) Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.